NY-WOLTERS-KLUWER
17.4.2024 14:01:26 CEST | Business Wire | Press release
Wolters Kluwer, a global leader in information, software, and services for professionals, today announced Atul Dubey as General Manager of its Finance, Risk and Regulatory Reporting (FRR) business, part of its Corporate Performance & ESG (CP & ESG) division. Suzanne Konstance will succeed Dubey as General Manager of Wolters Kluwer Legal & Regulatory U.S, part of the company’s Legal & Regulatory division, effective May 1.
Karen Abramson, CEO of Wolters Kluwer CP & ESG, commented: “Atul’s deep understanding of the financial regulatory and risk landscape will be critical strengths as he takes this global leadership role for Wolters Kluwer FRR, driving growth and relentless innovation for our clients.”
Wolters Kluwer FRR’s award-winning OneSumX suite of solutions support financial institutions through innovative technology that enables and empowers clients to stay compliant with everchanging regulatory requirements, manage uncertainty through financial risk management offerings and drive efficiency.
“Serving over 800 customers in 40 countries, OneSumX for FRR has a significant global role in the financial services ecosystem,” Dubey commented. “I look forward to working with Karen and the talented team to drive product enhancement and innovation, delivering value to our clients, partners and regulators.”
Dubey joined Wolters Kluwer in 2016 as Chief Strategy Officer, with a strong background in institutional banking, having held senior leadership roles at Citigroup, S&P Global and Booz Allen.
Martin O’Malley, CEO of Wolters Kluwer Legal & Regulatory: “I am grateful for Atul’s incisive leadership, which has seen our solutions, services and customers thrive during a period of unparalleled transformation for our industry. At the same time, I am excited to welcome Suzanne to our division. Her deep industry expertise, commitment to innovation and experience in creating vibrant team cultures will continue to push our U.S. business to new heights.”
Konstance held leadership positions in Wolters Kluwer for eight years, in which she built a strong track record in product management, strategy and go-to-market. She most recently served as Vice President & Segment Leader of Lien Solutions for the Wolters Kluwer Compliance Solutions business unit – a part of the company’s Financial & Corporate Compliance (FCC) division. She successfully engaged in launching AI-enabled products to transform the business while managing to achieve an above-market growth rate. Prior to joining Wolters Kluwer, Konstance held senior roles at Pitney Bowes, Citibank, and MetLife.
“By combining unparalleled domain expertise with the latest AI-driven technology, Wolters Kluwer Legal & Regulatory U.S. is uniquely positioned to help today’s legal professionals achieve measurable efficiencies and gain valuable insights,” Konstance said. “I am eager to begin collaborating with this dynamic team as we chart a path toward continued growth.”
Wolters Kluwer Legal & Regulatory U.S. is a leading provider of information, business intelligence, and regulatory and legal workflow solutions for legal, corporate, and compliance professionals across several industries. Legisway, Wolters Kluwer’s award-winning and all-in-one SaaS legal information and contract management solution for corporate legal departments, recently launched new AI-enhanced functionality, accelerating the contract review process by enabling legal departments to effortlessly query their contracts using advanced natural language processing.
For more information about Wolters Kluwer, please visit: www.wolterskluwer.com
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417358923/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom